The FDA action follows presentation of results in August during the European Society of Cardiology 2020 Virtual Congress.
FDA has granted dapagliflozin (Farxiga, AstraZeneca) breakthrough therapy designation for patients with chronic kidney disease (CKD), both with and without type 2 diabetes (T2D).
The decision comes following the presentation of results from the DAPA-CKD trial, which showed that dapagliflozin brought a 39% decline in the risk of declining renal function or cardiovascular or renal death when given alongside standard of care. Results also showed dapagliflozin reduced the risk of death from any cause by 31%.
The findings were presented August 30 during the European Society of Cardiology 2020 Virtual Congress.
In the United States, 37 million patients have CKD, which can lead to the need for dialysis and is strongly linked with heart disease and stroke. CMS has taken steps to prevent patients from progressing to later-stage kidney disease, both to preserve quality of life and to reduce the large share of Medicare spending that goes for kidney-related care. Federal officials estimate that while 1% of Medicare beneficiaries have kidney disease, it accounts for 7% of all spending.
“There is a serious, unmet need for better and earlier treatment options for patients with chronic kidney disease,” Mene Pangalos, executive vice president, BioPharmaceuticals R&D for AstraZeneca, said in a statement. “Following the ground-breaking DAPA-CKD results, the breakthrough therapy designation is further testament to Farxiga’s potential to slow the progression of chronic kidney disease. We look forward to working with the FDA to make Farxiga available to patients as quickly as possible.”
Dapagliflozin is part of a class of drugs called sodium glucose co-transporter 2 (SGLT2) inhibitors, which were originally developed to treat T2D. The drugs work by targeting a protein that blocks the mechanism that causes the body to reabsorb excess glucose; instead, it is expelled from the body through the urine.
SGLT2 inhibitors have also been found to be effective in reducing the risk of heart failure specifically, dapagliflozin is approved to reduce the risk of hospitalization for heart failure in patients with T2D and established cardiovascular (CV) disease or multiple CV risk factors. In May, FDA approved dapagliflozin to reduce the risk of CV death and hospitalization for heart failure in adults with heart failure with reduced ejection fraction, whether or not they have T2D.
FDA Approves Vadadustat for Anemia in Patients With CKD Undergoing Dialysis
March 28th 2024The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.
Read More
More Needs to Be Done to Reduce Racial Disparities in Home Dialysis
March 24th 2023On this episode of Managed Care Cast, we speak with Virginia Wang, PhD, and Matthew L. Maciejewski, PhD, who talk about their recent study on racial disparities in home dialysis, and what more needs to be done to increase uptake and reduce disparities in home dialysis for non-White patients.
Listen
Dr Madeleine McDowell Discusses How CKD Disparities, Social Challenges Impact Health Care Access
October 4th 2023Madeleine McDowell, MD, hopes these data insights will help change providers' behavior in terms of adopting earlier and more regular screening for chronic kidney disease (CKD).
Read More
Advocating for All Patients With Chronic Kidney Disease
April 26th 2022Chronic kidney disease is the fastest-growing noncontagious disease in the United States. On this episode of Managed Care Cast, we speak with Mike Spigler, vice president of patient support and education for the American Kidney Fund, who is spearheading the Unknown Causes of Kidney Disease Project, which aims to help underserved patients get to the root cause of their kidney disease, while also helping to solve this mystery for a broader patient population.
Listen